Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Breakthrough in antigen recognition: TRACeR-I enhances immune targeting

Researchers describe TRACeR-I, a protein platform that can be used to engineer immune responses.

19 Dec 2024

Breakthrough discovery opens doors for targeting adhesion GPCRs with drugs

Almost 35% of drugs approved by the Food and Drug Administration work by targeting G protein-coupled receptors (GPCRs), proteins embedded in cell membranes that allow cells to communicate with each other.

18 Dec 2024

Breakthrough pig kidney transplant ends dialysis for Alabama woman

An Alabama woman is free from dialysis and in better health after surgeons at NYU Langone Health performed a gene-edited pig kidney transplant last month.

17 Dec 2024

Chemical compound lights up treatment-resistant cancers on imaging scans

Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that could help medical professionals better target and treat cancer.

17 Dec 2024

Collaborative project seeks to close diagnostic gap in asthma care

Asthma affects more than 260M people worldwide and nearly 28M people in the U.S. alone, where, on average, 10 people die from attacks of the chronic disease each day.

16 Dec 2024

A new era of targeted therapy with antibody–drug conjugates

TBC

From Sino Biological Inc. 16 Dec 2024

Fairjourney Biologics establishes Scientific Advisory Board

FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced it has established a Scientific Advisory Board (SAB) to support its strategy for ongoing growth and innovation.

16 Dec 2024

The risks of reversed chirality: Study highlights dangers of mirror organisms

The study on mirror bacteria highlights risks of immune evasion and ecological threats, calling for collaboration to ensure safe synthetic biology practices.

16 Dec 2024

Targeted gene therapy shuts down cancer cells' energy centers

Researchers are shining a light on cancer cells' energy centers – literally – to damage these power sources and trigger widespread cancer cell death.

14 Dec 2024

Skin as an immune hero: Fighting infections with self-made antibodies

Researchers uncover how the skin autonomously produces antibodies through specialized immune structures, maintaining microbial balance and preventing infections.

12 Dec 2024

New hepatitis B vaccine offers superior protection for people with HIV

A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn't respond to prior vaccination, according to the results of an international study led by a Weill Cornell Medicine investigator.

11 Dec 2024

Skin-friendly bacteria could revolutionize vaccination

Imagine a world in which a vaccine is a cream you rub onto your skin instead of a needle a health care worker pushes into your one of your muscles.

11 Dec 2024

Next-generation cell-penetrating antibodies could transform cancer treatment

A news feature on the research paper "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition" by Rackear et al. was published in Oncotarget's Volume 15 on November 22, 2024, titled "Advancements in cell-penetrating monoclonal antibody treatment."

11 Dec 2024

Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM).

10 Dec 2024

Interim analysis of STOMP study finds no efficacy for tecovirimat in mild to moderate Mpox cases

The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international clinical trial called the Study of Tecovirimat for Mpox (STOMP).

10 Dec 2024

New triplet therapies show promise for relapsed and newly diagnosed leukemias

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias.

9 Dec 2024

First-in-class monoclonal antibody shows promise for rare, aggressive hyperinflammatory condition

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.

9 Dec 2024

Scientists uncover genetic code driving tumor formation and spread

A group of scientists at VCU Massey Comprehensive Cancer Center has revealed a new genetic code that acts like a cancer ringleader, recruiting and deploying a gang of tumor cells to incite a biological turf war by invading healthy organs and overpowering the normal cells.

9 Dec 2024

Study provides the first evidence of genetic predisposition to breast cancer metastasis

Ninety percent of cancer deaths are due to the spread of cancer, not complications from the original tumor.

9 Dec 2024

Novel drug combination shows promise for CLL treatment

A novel, fixed-duration drug combination - consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug - shows deep and durable responses in patients with chronic lymphocytic leukemia (CLL), Dana-Farber Cancer Institute investigator Jennifer Brown, MD, PhD, reports at the 66th American Society for Hematology (ASH) Annual Meeting and Exposition, on behalf of the trial investigators.

9 Dec 2024